Advertisement

Überblick über die therapeutischen Möglichkeiten des fortgeschrittenen Prostatakarzinoms

  • G. R. Ludwig

Zusammenfassung

Hat ein Prostatakarzinom die Organgrenzen so weit überschritten wie im Stadium T4 oder liegen bei einem geringergradigen Tumorstadium Lymphknoten und/oder Fernmetastasen vor, so handelt es sich um einen inkurablen Zustand. Wir sprechen dann vom fortgeschrittenen Prostatakarzinom.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bartsch H, Horst HJ, Becker H, Nehse G (1977) Sex hormone binding globulin binding capacity, testosterone, 5α-dihydrotestosterone, oestradiol und prolactin in plasma of patients with prostatic carcinoma under various types of hormonal treatment. Acta Endocrinol 85: 650PubMedGoogle Scholar
  2. Beland G (1986) Clinical efficacy of complete androgen blockade: controlled studies of one year or more — castration + anandron (experience canadienne). Presented at: Second Int Symp Prostatic Cancer, Paris March 16–18Google Scholar
  3. Benson RC jr, Gill GM (1986) Estramustine phosphate compared with diethylstilboestrol. A randomized, double blind, crossover trial for stage D prostate cancer. Am J Clin Oncol 9: 341Google Scholar
  4. Bracci U, di Silverio F (1977) Role of cyproterone acetate in urology. In: Martini L, Motta M (eds): androgens and antiandrogens, Raven Press, New York, p 333Google Scholar
  5. Brisset JM (1986) Should antiandrogens be associated to castration in current practice? Presented at: Second Int Symp Prostatic Cancer, Paris, March 16–18Google Scholar
  6. Byar DP (1973) The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate. Cancer 32: 1126PubMedCrossRefGoogle Scholar
  7. Geller J, Albert JD (1985) DHT in prostate cancer tissue — a guide to management and therapy. The Prostate 6: 19PubMedCrossRefGoogle Scholar
  8. Hartley-Asp G, Gunnarsson PO (1982) Growth and cell survival following treatment with estramustine, nor-nitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line (DU 145). J Urol 127: 818PubMedGoogle Scholar
  9. Hoogendijk E, de Voogt HJ (1986) Treatment of advanced prostatic cancer with anti-androgens alone and a combination of anti-androgen with anti-prolactine — a pilot study. Urol Res 14: 129PubMedCrossRefGoogle Scholar
  10. Huggins Ch, Hodges CV (1941) Studies on prostatic cancer I. Cancer research 1: 293Google Scholar
  11. Isaacs JT, Coffey DS (1981) Adaption versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation as studied in the Dunning R — 3327 H adenocarcinoma. Cancer Res 41: 5070PubMedGoogle Scholar
  12. Isaacs JT, Coffey DS (1982) Animal models in the study of prostatic growth. In: Chisholm GD, Williams DI (eds): Scientific foundations of urology. London, William Heinemann Medical Books Ltd, p 743Google Scholar
  13. Isaacs JT (1984) The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. The Prostate 5: 1PubMedCrossRefGoogle Scholar
  14. Jacobi GH, Altwein JE (1979) Bromocriptin als Palliativtherapie beim fortgeschrittenen Prostakarzinom. Experimentelles und klinisches Profil eines Medikamentes. Urol Int 34: 266Google Scholar
  15. Jacobi GH, Hohenfellner R (eds) (1982) Prostate cancer. Williams and Wilkins, Baltimore. Joensson G, Hoegberg B, Nilsson T (1977) Treatment of advanced prostatic carcinoma with estramustine phosphate (Estracyt®). Scand J Urol Nephrol 11: 231Google Scholar
  16. Karr JP, Murphy GP (1985) Treatment of prostatic carcinoma with combinations of drugs and hormones. In: Regulation of androgen activity. Bruchowsky N, Chapdelaine A, Neumann F (eds) Congressdruck R Bruckner, Berlin, p 81Google Scholar
  17. Klosterhalfen H, Becker H (1983) Antiandrogentherapie des Prostatakarzinoms — Klinische Erfahrungen mit Androcur® - Androcur®-Depot. In: Klosterhalfen H (Hrsg): Therapie des fortgeschrittenen Prostatakarzinoms. Schering AG, Berlin, p 63Google Scholar
  18. Labrie F, Dupont A, Belanger A, Lacoursiere Y, Raynaud JP, Husson JM, Gareau J, Fazekas A, Sandow J, Monfette G, Girard JG, Emond JP, Houle JG (1983) New approach in the treatment of prostate cancer: complete instead of partial withdrawl of androgens. The Prostate 4: 579PubMedCrossRefGoogle Scholar
  19. Labrie F, Dupont A, Belanger A, Lefebre FA, Cusan L, Monfette G, Laberge J-G, Emond JP, Raymond JP, Husson JM, Fazekas A (1983) New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen. J steroid Biochem 19: 999PubMedCrossRefGoogle Scholar
  20. Leistenschneider W, Nagel R (1980) Estracyt therapy of advanced prostatic cancer with special reference to control of therapy with cytology and DNA — cytophotometry. Eur Urol 6: 111PubMedGoogle Scholar
  21. Leistenschneider W, Nagel R (1983) Estracyt®-Therapie beim fortgeschrittenen Prostatakarzinom: Ergebnisse einer klinisch und zytologisch kontrollierten, prospektiven Studie. Akt Urol 14: 127Google Scholar
  22. Ludwig G, Sandow J, Pauthner H (1986) Die Behandlung des fortgeschrittenen Prostatakarzinoms mit Buserelin-Implantat. Verh Dtsch Ges Urol 38. Tagung, Würzburg (im Druck)Google Scholar
  23. Moguilewsky M, Fiet J, Tournemine C, Raynaud JP (1986) Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer. J steriod Biochem 24: 139CrossRefGoogle Scholar
  24. Murphy GP (1977) Current status of therapy in prostatic cancer. In: Tannenbaum M (ed), Urologie pathology: the prostate. Lea & Felbiger, PhiladelphiaGoogle Scholar
  25. Murphy GP, Beckley S, Brady MF, Chu TM, De Kernion JB, Dhabuwala C, Gaeta JF, Gibbons RP, Loening SG, Mc Kiel CF, Mc Leod DG, Pontes JE, Prout GR, Scardino PT, Schlegel JU, Schmidt JD, Scott WW, Slack NH, Soloway MS (1983) Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51: 1264PubMedCrossRefGoogle Scholar
  26. Nagel R, Leistenschneider W (1983) Chemotherapie des Prostatakarzinoms. In: Klosterhalfen H (Hrsg): Therapie des fortgeschrittenen Prostatakarzinoms. Schering AG, Berlin, p 55Google Scholar
  27. Neumann F, Schenck B (1983) Pharmakologische Grundlagen und rationale Basis der verschiedenen endokrinen Therapieverfahren. In: Klosterhalfen H (Hrsg): Therapie des fortgeschrittenen Prostatakarzinoms. Schering AG, Berlin, p 15Google Scholar
  28. Paulson DF, Cline WA, Hinshaw W and the Uro-Oncology Research Group (1982) Extended field radiation therapy vs. delayed hormonal therapy in node positive prostatic adenocarcinoma. J Urol 127: 935Google Scholar
  29. Pavone-Macaluso M (1982) Value of chemotherapy in prostate cancer management and present data on EORTC therapy trials. In: Jacobi HG, Hohenfellner R (eds): Prostate cancer, Williams and Wilkins, Baltimore London, p 321Google Scholar
  30. Pavone-Macaluso M, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R (1986) Comparison of the diethylstilboestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer, Urological Group. J Urol 136: 624Google Scholar
  31. Redding TW, Schally AV (1983) Investigation of the contribution of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327 H prostate cancer model. The Prostate 6: 219CrossRefGoogle Scholar
  32. Schally AV, Kastin AJ, Arimura A (1972) FSH-releasing hormone and LH-releasing hormone. Hormones 30: 83Google Scholar
  33. Schroeder FH (1984) Treatment response criteria for prostatic cancer. The Prostate 5: 181PubMedCrossRefGoogle Scholar
  34. Schroeder FH (1986) Hormonabhängiges Wachstum des Prostata-Carcinoms — Adaptation oder Selektion? Verh Dtsch Ges Urol 38. Tagung, Würzung (im Druck)Google Scholar
  35. Tew KD, Hartley-Asp B (1984) Cytotoxic properties of estramustine unrelated to alkalating and steroid constituents. Urology 23: 28PubMedCrossRefGoogle Scholar
  36. The Veterans Administration Cooperative Urological Research Group (1967) Carcinoma of the prostate: treatment comparisons. J Urol 98: 516Google Scholar
  37. Torti FM (1984) Hormonal therapy for prostate cancer. New England J Med 311: 1313CrossRefGoogle Scholar
  38. Trachtenberg J, Halpern N, Pont A (1983) Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. J Urol 130: 152PubMedGoogle Scholar
  39. Tunn UW, Mouhanna H (1986) Responsekriterien als Variable bei der Evaluation des Therapieeffektes beim Prostatakarzinom. Verh Dtsch Ges Urol, 38. Tagung, Mainz. Thieme Stuttgart New York, S. 158–160Google Scholar
  40. de Voogt HJ, Soloway MS (1985) Prostate Cancer. Hoechst meducation up-date. Series hormones. Hoechst AG, FrankfurtGoogle Scholar
  41. de Voogt HJ, Smith PhH, Pavone-Macaluso M, de Pauw M, Suciu S and members of the European Organization for Research on Treatment of Cancer, Urological Group (1986). J Urol 135: 303PubMedGoogle Scholar
  42. Waxman JH, Wass J AH, Hendry WF, Whitfield HN, Barry P, Besser GN, Malpas JS, Oliver RTD (1983) Treatment of advanced prostatic cancer with Buserelin, an analogue of gonadotropin-releasing hormone. Brit J Urol 55: 737PubMedCrossRefGoogle Scholar
  43. Waxman J (1985) Die klinische Anwendung von Buserelin bei Patienten mit fortgeschrittenem Prostatakarzinom: Hormonsekretion während der Langzeitbehandlung mit Buserelin Nasalspray und erste Erfahrungen mit dem Buserelin Implantat. In: Altwein JE, Ludwig G (Hrsg): Neue Wege in der Therapie des fortgeschrittenen Prostatakarzinoms mit LH-RH-Agonisten. PMI- Verlag, Frankfurt am, p 103Google Scholar
  44. Wenderoth UD, Jacobi GH (1983) Gonadotropin-releasing hormone analogues for palliation of carcinoma of the prostate. World J Urol 1: 40CrossRefGoogle Scholar
  45. Weissbach L (1982) Exspektative Beobachtungen beim Prostatakarzinom im Stadium Tis, T1–2, G1 In: Faul P, Altwein J (Hrsg) Aktuelle Diagnostik und Therapie des Prostatakarzinoms. Informed, Gräfelfing, p 97Google Scholar
  46. Williams G (1984) Ketoconazole for prostate cancer. Lancet 8404: 696CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • G. R. Ludwig

There are no affiliations available

Personalised recommendations